Premium
Comparative proteomic analysis in children with idiopathic short stature ( ISS ) before and after short‐term recombinant human growth hormone (rh GH ) therapy
Author(s) -
Heo Sun Hee,
Choi JinHo,
Kim YooMi,
Jung ChangWoo,
Lee Jin,
Jin Hye Young,
Kim GuHwan,
Lee Beom Hee,
Shin Choong Ho,
Yoo HanWook
Publication year - 2013
Publication title -
proteomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.26
H-Index - 167
eISSN - 1615-9861
pISSN - 1615-9853
DOI - 10.1002/pmic.201200131
Subject(s) - idiopathic short stature , recombinant dna , human growth hormone , endocrinology , medicine , growth hormone , short stature , western blot , proteomics , hormone therapy , protein expression , hormone , biology , biochemistry , gene , cancer , breast cancer
This study was undertaken to identify growth hormone ( GH ) responsive proteins and protein expression patterns by short‐term recombinant human growth hormone (rh GH ) therapy in patients with idiopathic short stature ( ISS ) using proteomic analysis. Seventeen children (14 males and three females) with ISS were included. They were treated with rh GH at a dose of 0.31 ± 0.078 mg/kg/week for 3 months. Immunodepletion of six highly‐abundant serum proteins followed by 2 D DIGE analysis, and subsequent MALDI TOF MS , were employed to generate a panel of proteins differentially expressed after short‐term rh GH therapy and verify the differences in serum levels of specific proteins by rh GH therapy. Fourteen spots were differentially expressed after rh GH treatment. Among them, apo E and apo L ‐1 expression were consistently enhanced, whereas serum amyloid A was reduced after rh GH therapy. The differential expressions of these proteins were subsequently verified by W estern blot analysis using sera of the before and after rh GH treatment. This study suggests that rh GH therapy influences lipoprotein metabolism and enhances apo L ‐1 protein expression in ISS patients.